Sorrento’s Resiniferatoxin Receives the US FDA’s Clearance to Initiate P-II Trial for the Treatment of Knee Pain in Patients with Osteoarthritis

 Sorrento’s Resiniferatoxin Receives the US FDA’s Clearance to Initiate P-II Trial for the Treatment of Knee Pain in Patients with Osteoarthritis

Sorrento to License Dyadic’s DYAI-100 and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

Shots:

  • The P-II trial will assess the efficacy & safety of RTX across several dose groups vs PBO in patients with a mod. to sev. OAK pain. The study follows the P-Ib trial results of RTX
  • The P-Ib data demonstrated the significant efficacy supporting RTX for long term refractory OA pain, pain relief observed in patients with advanced OA disease, and sustained pain relief last beyond 6 mos.
  • The program continues with P-II & P-III trial in larger patient populations, while the P-II trial will be targeted to identify the RP3D. The company has decided to add an active comparator (injectable corticosteroid) in the current trial protocol to give the durability of OA pain relief response

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Analyze Markets

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post